{"ticker": {"uuid": "f13b7bfa-14cb-485d-ab72-7f0ab1d07440", "symbol": "EIKN", "name": "Eikon Therapeutics, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Eikon Therapeutics: Behind The Rough Debut (NASDAQ:EIKN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOejBybnlIemhaN1RxMEc1cmh1YmtVUDFwRVUwdC1La3JET1gyajR5YXpibHY1YUlvRHJobFpDeVAwTkVTT0VoZ3FYNUxsaFNDOVR1SDQ1QkNQc0ZLUjdBRkVEZC1xdW5iVVNibGFSajhCb3JUek1EeTdjTHVZYWRKSGxOOVBUQ2ZHTGc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-20T16:05:00+00:00", "published_display": "20 Jul 2026 16:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress", "summary": "Eikon Therapeutics announced that seven abstracts covering progress across its lead oncology programs have been accepted for presentation at the 2026 European Society of Medical Oncology (ESMO) Congress. These presentations will include updated data from ongoing trials for EIK100", "url": "https://ca.finance.yahoo.com/news/eikon-therapeutics-announces-seven-abstracts-120000454.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-20T12:10:35", "published_display": "20 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seven Eikon abstracts include lung and prostate cancer studies at ESMO", "summary": "Eikon Therapeutics (Nasdaq: EIKN) announced that seven abstracts detailing progress across its oncology pipeline have been accepted for presentation at the 2026 European Society of Medical Oncology (ESMO) Congress. These abstracts include updated Phase 2 data for EIK1001 in non-s", "url": "https://www.stocktitan.net/news/EIKN/eikon-therapeutics-announces-seven-abstracts-accepted-for-kus5ua8i9dmg.html", "source_name": "Stock Titan", "published_at": "2026-07-20T12:10:35", "published_display": "20 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Eikon Therapeutics (EIKN) Short Interest & Short Float | Updated Jul 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE5IS3UwUm1NaXVnQmZMWEVRSkVUTFQ3a1JzTWVlRTQxaGlLcFNDNnVrMU9MeXVnX0pGaU42YXlxd3RVSzUtdDZPeGxwT0hnSVpFYUFHdXh1LVFQTmR2dDlaUHZWclBtQkJ4Y0l2bFpB?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Eikon Therapeutics, Inc. (EIKN) Stock a Biotech Growth Opportunity Despite Limited Q1 Updates?", "summary": "Eikon Therapeutics, Inc. (EIKN) is highlighted as a promising biopharmaceutical stock, despite limited Q1 updates, following BofA Securities lowering its price target while maintaining a Buy rating. The company recently achieved a significant milestone with its upcoming inclusion", "url": "https://www.insidermonkey.com/blog/is-eikon-therapeutics-inc-eikn-stock-a-biotech-growth-opportunity-despite-limited-q1-updates-1793944/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-07-02T19:41:14", "published_display": "02 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics to Join Russell 3000 Index Following Annual Reconstitution", "summary": "Eikon Therapeutics, Inc. (EIKN), a biotechnology company, is set to join the Russell 3000 Index as part of the 2026 annual reconstitution. This inclusion means Eikon Therapeutics will be automatically added to the appropriate growth and value indexes, as well as the Russell 1000 ", "url": "https://www.moomoo.com/news/post/72083605/eikon-therapeutics-to-join-russell-3000-index-following-annual-reconstitution", "source_name": "Moomoo", "published_at": "2026-06-30T01:40:20", "published_display": "30 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Eikon Therapeutics, Inc. \u2013 NASDAQ:EIKN", "summary": "This page provides financial data on Eikon Therapeutics, Inc. (NASDAQ: EIKN), specifically focusing on its enterprise value to revenue forward metric. The content highlights a specific financial period and value, along with information about data providers and copyright.", "url": "https://www.tradingview.com/symbols/NASDAQ-EIKN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T01:40:19", "published_display": "30 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics, Inc.(NasdaqGS:EIKN) added to Russell Microcap Growth Benchmark Index", "summary": "Eikon Therapeutics, Inc. (NasdaqGS:EIKN) has been added to the Russell Microcap Growth Benchmark Index. This inclusion is one of several recent additions of Eikon Therapeutics to various Russell indices, including the Russell 2000 Index, Russell Microcap Value Benchmark Index, an", "url": "https://www.marketscreener.com/news/eikon-therapeutics-inc-nasdaqgs-eikn-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08cf326", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T23:09:35", "published_display": "29 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 2000 Index", "summary": "Eikon Therapeutics, Inc. (NasdaqGS: EIKN) has been added to the Russell 2000 Index, as well as several other Russell indices including the Microcap Value Benchmark, 2000 Value Benchmark, Microcap Growth Benchmark, 2000 Growth Benchmark, 3000E Growth Benchmark, and Microcap Index.", "url": "https://www.marketscreener.com/news/eikon-therapeutics-inc-nasdaqgs-eikn-added-to-russell-2000-index-ce7f5fdfdc8ef52c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T21:56:00", "published_display": "29 Jun 2026 21:56", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 2000 Growth Benchmark", "summary": "Eikon Therapeutics, Inc. (NasdaqGS:EIKN) has been added to the Russell 2000 Growth Benchmark as of June 29, 2026. This inclusion is part of a series of additions for Eikon Therapeutics to various Russell indices, including the Russell 2000 Index, Russell Microcap Value Benchmark,", "url": "https://www.marketscreener.com/news/eikon-therapeutics-inc-nasdaqgs-eikn-added-to-russell-2000-growth-benchmark-ce7f5fded18cf327", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:40:34", "published_display": "29 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 3000E Growth Benchmark", "summary": "Eikon Therapeutics, Inc. (NasdaqGS:EIKN) has been added to the Russell 3000E Growth Benchmark. This news comes shortly after the company was also added to the Russell Microcap Index and the S&P Global BMI Index, indicating increased recognition within key market indices. The comp", "url": "https://www.marketscreener.com/news/eikon-therapeutics-inc-nasdaqgs-eikn-added-to-russell-3000e-growth-benchmark-ce7f5fdedf8ffe23", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T09:39:26", "published_display": "29 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 2000 Value Benchmark", "summary": "Eikon Therapeutics, Inc. (NasdaqGS: EIKN) has been added to the Russell 2000 Value Benchmark index. This inclusion is part of several recent additions to various Russell indices, including the Russell 2000 Index, Russell Microcap Value Benchmark Index, and Russell Microcap Growth", "url": "https://www.marketscreener.com/news/eikon-therapeutics-inc-nasdaqgs-eikn-added-to-russell-2000-value-benchmark-ce7f5fdfdb89f126", "source_name": "www.marketscreener.com", "published_at": "2026-06-28T15:10:18", "published_display": "28 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Eikon Therapeutics, Inc. \u2013 BOATS:EIKN", "summary": "The article discusses the Enterprise Value to EBIT forward metric for Eikon Therapeutics, Inc. (EIKN). It provides a brief overview of the company's financial data as listed on TradingView, indicating that the market is currently closed with no trades. The content primarily focus", "url": "https://www.tradingview.com/symbols/BOATS-EIKN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T23:09:35", "published_display": "26 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Eikon Therapeutics, Inc. \u2013 NASDAQ:EIKN", "summary": "This article focuses on the \"Price to book forward\" metric for Eikon Therapeutics, Inc., traded on the Nasdaq Stock Market under the ticker EIKN. It appears to be an announcement or a data point provided by TradingView, indicating a specific financial ratio for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-EIKN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T23:09:35", "published_display": "26 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EIKN - Eikon Therapeutics Inc Short Interest", "summary": "This article provides comprehensive financial data for Eikon Therapeutics Inc. (EIKN), focusing on its short interest. It details key financial metrics, stock performance, insider and institutional ownership, analyst recommendations, and various valuation ratios. The data highlig", "url": "https://finviz.com/stock?t=EIKN&ta=1&p=d&ty=si", "source_name": "Finviz", "published_at": "2026-06-26T12:10:11", "published_display": "26 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics to Join the Russell 3000\u00ae Index", "summary": "Eikon Therapeutics, a late-stage clinical biopharmaceutical company, announced its inclusion in the broad-market Russell 3000\u00ae Index, effective after the US market closes on June 26, 2026. This addition highlights Eikon's progress as a publicly traded entity and its growing prese", "url": "https://www.globenewswire.com/news-release/2026/06/25/3317939/0/en/eikon-therapeutics-to-join-the-russell-3000-index.html", "source_name": "GlobeNewswire", "published_at": "2026-06-26T10:09:44", "published_display": "26 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Eikon Therapeutics, Inc. \u2013 NASDAQ:EIKN", "summary": "This article provides access to the enterprise value to EBITDA forward data for Eikon Therapeutics, Inc. (NASDAQ: EIKN) on TradingView. It appears to be a financial data page rather than a traditional article. The page is a directory for financial metrics and general company info", "url": "https://www.tradingview.com/symbols/NASDAQ-EIKN/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T10:09:18", "published_display": "26 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Eikon Therapeutics, Inc. \u2013 NASDAQ:EIKN", "summary": "This article provides the \"Price to sales forward\" value for Eikon Therapeutics, Inc. (NASDAQ: EIKN). It is a finance-related piece from TradingView, focusing on the company's financial metrics. The specific value for the forward price-to-sales ratio is presented as part of the c", "url": "https://www.tradingview.com/symbols/NASDAQ-EIKN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T03:41:18", "published_display": "26 Jun 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics, Inc. Actuals & Estimates (NASDAQ:EIKN)", "summary": "This article provides actuals and estimates for Eikon Therapeutics, Inc. (NASDAQ:EIKN), detailing its financial performance, stock price dynamics, and analyst forecasts. It covers the current stock price, historical highs and lows, market capitalization, volatility, and upcoming ", "url": "https://www.tradingview.com/symbols/NASDAQ-EIKN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T02:41:18", "published_display": "26 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Eikon Therapeutics, Inc. \u2013 BOATS:EIKN", "summary": "This article provides the \"Price to book forward\" financial metric for Eikon Therapeutics, Inc. (EIKN), listed on the Blue Ocean Alternative Trade System (BOATS). It presents the period, value, change, and percentage change. The content appears to be a snapshot from a financial d", "url": "https://www.tradingview.com/symbols/BOATS-EIKN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T00:41:18", "published_display": "26 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Eikon Therapeutics, Inc. \u2013 BOATS:EIKN", "summary": "This article provides financial information for Eikon Therapeutics, Inc. (EIKN) on the Blue Ocean Alternative Trade System (BOATS), specifically focusing on its forward price-to-earnings ratio. It indicates that the market is currently closed with no trades. The content is primar", "url": "https://www.tradingview.com/symbols/BOATS-EIKN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T23:09:18", "published_display": "25 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics to Join Russell 3000 Index After Annual Reconstitution", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/eikon-therapeutics-join-russell-3000-204829026.html", "source_name": "MT Newswires", "published_at": "2026-06-25T20:48:29+00:00", "published_display": "25 Jun 2026 20:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics to join Russell 3000 Index on Friday", "summary": "Eikon Therapeutics (NASDAQ:EIKN) will be added to the Russell 3000 Index after the U.S. market closes on Friday, following the annual reconstitution of Russell U.S. Indexes. The biopharmaceutical company is currently trading at $9.85 with a market capitalization of $521 million, ", "url": "https://www.investing.com/news/company-news/eikon-therapeutics-to-join-russell-3000-index-on-friday-93CH-4761442", "source_name": "Investing.com", "published_at": "2026-06-25T21:41:18", "published_display": "25 Jun 2026 21:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics to join Russell 3000 Index on Friday By Investing.com", "summary": "Eikon Therapeutics, Inc. (NASDAQ:EIKN) will be added to the Russell 3000 Index after the U.S. market closes on Friday, following the annual reconstitution of the Russell U.S. Indexes. The company currently trades at $9.85 with a market capitalization of $521 million, though share", "url": "https://ca.investing.com/news/stock-market-news/eikon-therapeutics-to-join-russell-3000-index-on-friday-93CH-4708308", "source_name": "Investing.com Canada", "published_at": "2026-06-25T20:25:47", "published_display": "25 Jun 2026 20:25", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Eikon Therapeutics, Inc. \u2013 NASDAQ:EIKN", "summary": "This article provides a financial snapshot of Eikon Therapeutics, Inc. (NASDAQ: EIKN), specifically focusing on its forward price-to-earnings ratio. It indicates that the market is currently closed for the stock, with no trades recorded. The content seems to be a financial data p", "url": "https://www.tradingview.com/symbols/NASDAQ-EIKN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T15:40:47", "published_display": "25 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EIKN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed forecast and price target for Eikon Therapeutics, Inc. (EIKN) stock, including analyst ratings and future predictions. It covers current market performance, historical highs and lows, volatility, market capitalization, and upcoming earnings report", "url": "https://www.tradingview.com/symbols/NASDAQ-EIKN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-24T02:09:44", "published_display": "24 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics Ord Shs (EIKN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Eikon Therapeutics Ord Shs (EIKN), detailing analyst ratings, target prices, and EPS estimates. Six analysts currently rate EIKN as a \"Buy\" with a target price suggesting a significant upside. The report also includes past EPS perfor", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eikn/earnings", "source_name": "TradingKey", "published_at": "2026-06-22T00:10:20", "published_display": "22 Jun 2026 00:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Stock: Buy TLR Combinatory Potential Only After Lock-Up Expiry (NASDAQ:EIKN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOOUxWelR4WFpBSHQ0SHFaNzBKRnZmazZ0Y09OV3N1MTVtUUJ0TmItTXdfYVJTZFpmRTlOT0xmMk12NjVKRW1yY3RLTkdkVHhhNTRRY0dzdDhDSFdDZnhtX3k3M0J3U2hGZEw1MzhLQVBuSVdEdEw3dk9YRnQxQjB2NXJKUTdfT0s5RFZLaDctRjV0Y2Y5QzR1Y2NlVHZ0Z1JmYTRuVm1xdk1MaEJ2b3hNTEVKbktmdw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cooper Companies Stock: Is COO Underperforming the Healthcare Sector?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPWkdoUDRJdkh3QndoZ3J2OHBvOEJlMUFEYjc1X3pLZGFXUlJ6eS1iNXhpYzNyd1NSZGxPOUdDM0xnZW9RcS1kdWNwR0xydVFVcEFGVmhfWWF5SFhYTmR5dXM0cTRIUENtbTc5bUpuNTNZQ0h0QWhMbnZDdGpfYjRWM2c3SWlCOHVJYTVoaUdDYnk2cTRKWWZTZHFvXzZDMTFmOGRUUUhyX3J6RUE?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics: Initiating Coverage With A Cautious Buy Rating (NASDAQ:EIKN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxObEdfNFZETEVGU3ZoQWVtd2haczVMb2ZodUlSeHBVcEpLcmJ1NW9nN3FZRk1KRGlUc0dRcF9tSGUwT2E3ZjgyRDdCdTN3aHlfaXpJVklVZkhYWHpjTm82MHJGWHJoSG5FWFdyWExxamRnYmFwRjlqYy01MzcybGlmMUstUmk5WjRZV0U3SUtvSXF3bHM1eTBzYjd0Q3RFanlPQjByaHdYajk2QQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics Appoints Ma. Fatima Francisco to Board", "summary": "Eikon Therapeutics, Inc. has appointed Ma. Fatima D. Francisco as a Class I director to its board, effective June 15, 2026. She will serve on the Compensation Committee and receive an annual cash retainer of $50,000, along with an option to purchase 85,937 shares. This appointmen", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2431328/eikon-therapeutics-appoints-ma-fatima-francisco-to-board/", "source_name": "The Globe and Mail", "published_at": "2026-06-12T03:10:30", "published_display": "12 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Former P&G business leader joins drug developer Eikon\u2019s board", "summary": "Eikon Therapeutics (Nasdaq: EIKN) has appointed Ma. Fatima D. Francisco, a former CEO at Procter & Gamble, as an independent director to its Board, effective June 15, 2026. She will also join the Board\u2019s Compensation Committee. Francisco brings over 35 years of leadership experie", "url": "https://www.stocktitan.net/news/EIKN/eikon-therapeutics-announces-the-appointment-of-ma-fatima-d-8v8p4pynn1cd.html", "source_name": "Stock Titan", "published_at": "2026-06-11T08:12:47", "published_display": "11 Jun 2026 08:12", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New director and stock option grant at Eikon Therapeutics (NASDAQ: EIKN)", "summary": "Eikon Therapeutics (NASDAQ: EIKN) has appointed Ma. Fatima D. Francisco to its Board of Directors as a Class I director, effective June 15, 2026. She will serve until the company's 2027 annual stockholder meeting and will join the Board's Compensation Committee. Ms. Francisco wil", "url": "https://www.stocktitan.net/sec-filings/EIKN/8-k-eikon-therapeutics-inc-reports-material-event-30cfff571ea9.html", "source_name": "Stock Titan", "published_at": "2026-06-11T03:10:30", "published_display": "11 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eikon-therapeutics-announces-appointment-ma-120000780.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T12:00:00+00:00", "published_display": "08 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Overweight on Eikon stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPck1INFR2M2xaVEhfMUsxRFotM0NuT2p3TXZ4QVB1VlkxX2pKalhkLTZJYzE0RjhtR2VtUUJmYWZjUzktTVV4YjlNOHpNQzl6Wi01N09KZUFSOF9xTlRteGFUb29WQ21YSGk4RkdXajFtV1l1aGp6cS1vSjBvT0lxVXhDcmpQRi03cWlNYlFFRjllUmgxU2tySWJwanlMTGkxMUJxMmR5Y0NkVHNtWUctbk1mNEM?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eikon-therapeutics-presents-data-clinical-183000633.html", "source_name": "GlobeNewswire", "published_at": "2026-05-30T18:30:00+00:00", "published_display": "30 May 2026 18:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eikon-therapeutics-announces-availability-six-210500443.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T21:05:00+00:00", "published_display": "21 May 2026 21:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$EIKN stock is down 10% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOY1NBNEVzQmZheWt2TnJqbGVPaXByOEZxWk1SWnRWVWZSX3NINUhPb2hGNlFjWUNybkhUTGhpRDd2QTQxT0hWOTRCbURrMnNxT1hDMGhWVlFjaWw1bWZGNFpZenJKZGp0RmctSmdKVWJPcnhpQ3JFdFF1UHVMSDFLZWJUVnNDN1c5UkoweHJ5QkRTalFPQ2NZNUxRbFVnLTBaOUZR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Wedbush Cuts Price Target on Eikon Therapeutics to $5 From $7, Keeps Underperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-cuts-price-target-eikon-121145064.html", "source_name": "MT Newswires", "published_at": "2026-05-12T12:11:45+00:00", "published_display": "12 May 2026 12:11", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eikon-therapeutics-reports-first-quarter-200100054.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T20:01:00+00:00", "published_display": "11 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "After a $381M IPO, Eikon fully enrolls a stage 4 lung cancer study", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNWE5sd2s5YkY4NmlRamZnbzk3aVZqRFBUNDV0ZEsxY09COE90eThxWXdRMVZpVl84ODR5TTFqa3QzYUdYWElXaVdpWEhISHdDRjVYSnlaNE9TbUhuQjhUOUI0blJ0RjJQYVhmVnE1YXVXTzVYYU8zTUJxOFhuVFNfUlRSZTE2eU1UV0l2Rk11dV81RE1rYjdPR0t2TFJhZDlyeFlieW9VQnhzSlhybFF4SWRjSG13cTBq?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics (EIKN) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE5IZUE4dzN1YXQ5MldXd19RTnRFa0Y4b2JmLS1NTDJVdl9FZnVZUjlaNURYS3haSkFjeEp1dkhxTWVzQmpBWUZHU3VzRmJaNFp6UGNoczlVckd0RUtOeUxfOUZPdlpXQQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-02-17T08:53:50+00:00", "published_display": "17 Feb 2026 08:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Eikon Therapeutics: Behind The Rough Debut (NASDAQ:EIKN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOejBybnlIemhaN1RxMEc1cmh1YmtVUDFwRVUwdC1La3JET1gyajR5YXpibHY1YUlvRHJobFpDeVAwTkVTT0VoZ3FYNUxsaFNDOVR1SDQ1QkNQc0ZLUjdBRkVEZC1xdW5iVVNibGFSajhCb3JUek1EeTdjTHVZYWRKSGxOOVBUQ2ZHTGc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-20T16:05:00+00:00", "published_display": "20 Jul 2026 16:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress", "summary": "Eikon Therapeutics announced that seven abstracts covering progress across its lead oncology programs have been accepted for presentation at the 2026 European Society of Medical Oncology (ESMO) Congress. These presentations will include updated data from ongoing trials for EIK100", "url": "https://ca.finance.yahoo.com/news/eikon-therapeutics-announces-seven-abstracts-120000454.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-20T12:10:35", "published_display": "20 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seven Eikon abstracts include lung and prostate cancer studies at ESMO", "summary": "Eikon Therapeutics (Nasdaq: EIKN) announced that seven abstracts detailing progress across its oncology pipeline have been accepted for presentation at the 2026 European Society of Medical Oncology (ESMO) Congress. These abstracts include updated Phase 2 data for EIK1001 in non-s", "url": "https://www.stocktitan.net/news/EIKN/eikon-therapeutics-announces-seven-abstracts-accepted-for-kus5ua8i9dmg.html", "source_name": "Stock Titan", "published_at": "2026-07-20T12:10:35", "published_display": "20 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics (EIKN) Short Interest & Short Float | Updated Jul 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE5IS3UwUm1NaXVnQmZMWEVRSkVUTFQ3a1JzTWVlRTQxaGlLcFNDNnVrMU9MeXVnX0pGaU42YXlxd3RVSzUtdDZPeGxwT0hnSVpFYUFHdXh1LVFQTmR2dDlaUHZWclBtQkJ4Y0l2bFpB?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Eikon Therapeutics, Inc. (EIKN) Stock a Biotech Growth Opportunity Despite Limited Q1 Updates?", "summary": "Eikon Therapeutics, Inc. (EIKN) is highlighted as a promising biopharmaceutical stock, despite limited Q1 updates, following BofA Securities lowering its price target while maintaining a Buy rating. The company recently achieved a significant milestone with its upcoming inclusion", "url": "https://www.insidermonkey.com/blog/is-eikon-therapeutics-inc-eikn-stock-a-biotech-growth-opportunity-despite-limited-q1-updates-1793944/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-07-02T19:41:14", "published_display": "02 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics to Join Russell 3000 Index Following Annual Reconstitution", "summary": "Eikon Therapeutics, Inc. (EIKN), a biotechnology company, is set to join the Russell 3000 Index as part of the 2026 annual reconstitution. This inclusion means Eikon Therapeutics will be automatically added to the appropriate growth and value indexes, as well as the Russell 1000 ", "url": "https://www.moomoo.com/news/post/72083605/eikon-therapeutics-to-join-russell-3000-index-following-annual-reconstitution", "source_name": "Moomoo", "published_at": "2026-06-30T01:40:20", "published_display": "30 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Eikon Therapeutics, Inc. \u2013 NASDAQ:EIKN", "summary": "This page provides financial data on Eikon Therapeutics, Inc. (NASDAQ: EIKN), specifically focusing on its enterprise value to revenue forward metric. The content highlights a specific financial period and value, along with information about data providers and copyright.", "url": "https://www.tradingview.com/symbols/NASDAQ-EIKN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T01:40:19", "published_display": "30 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics, Inc.(NasdaqGS:EIKN) added to Russell Microcap Growth Benchmark Index", "summary": "Eikon Therapeutics, Inc. (NasdaqGS:EIKN) has been added to the Russell Microcap Growth Benchmark Index. This inclusion is one of several recent additions of Eikon Therapeutics to various Russell indices, including the Russell 2000 Index, Russell Microcap Value Benchmark Index, an", "url": "https://www.marketscreener.com/news/eikon-therapeutics-inc-nasdaqgs-eikn-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08cf326", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T23:09:35", "published_display": "29 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 2000 Index", "summary": "Eikon Therapeutics, Inc. (NasdaqGS: EIKN) has been added to the Russell 2000 Index, as well as several other Russell indices including the Microcap Value Benchmark, 2000 Value Benchmark, Microcap Growth Benchmark, 2000 Growth Benchmark, 3000E Growth Benchmark, and Microcap Index.", "url": "https://www.marketscreener.com/news/eikon-therapeutics-inc-nasdaqgs-eikn-added-to-russell-2000-index-ce7f5fdfdc8ef52c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T21:56:00", "published_display": "29 Jun 2026 21:56", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 2000 Growth Benchmark", "summary": "Eikon Therapeutics, Inc. (NasdaqGS:EIKN) has been added to the Russell 2000 Growth Benchmark as of June 29, 2026. This inclusion is part of a series of additions for Eikon Therapeutics to various Russell indices, including the Russell 2000 Index, Russell Microcap Value Benchmark,", "url": "https://www.marketscreener.com/news/eikon-therapeutics-inc-nasdaqgs-eikn-added-to-russell-2000-growth-benchmark-ce7f5fded18cf327", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:40:34", "published_display": "29 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 3000E Growth Benchmark", "summary": "Eikon Therapeutics, Inc. (NasdaqGS:EIKN) has been added to the Russell 3000E Growth Benchmark. This news comes shortly after the company was also added to the Russell Microcap Index and the S&P Global BMI Index, indicating increased recognition within key market indices. The comp", "url": "https://www.marketscreener.com/news/eikon-therapeutics-inc-nasdaqgs-eikn-added-to-russell-3000e-growth-benchmark-ce7f5fdedf8ffe23", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T09:39:26", "published_display": "29 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 2000 Value Benchmark", "summary": "Eikon Therapeutics, Inc. (NasdaqGS: EIKN) has been added to the Russell 2000 Value Benchmark index. This inclusion is part of several recent additions to various Russell indices, including the Russell 2000 Index, Russell Microcap Value Benchmark Index, and Russell Microcap Growth", "url": "https://www.marketscreener.com/news/eikon-therapeutics-inc-nasdaqgs-eikn-added-to-russell-2000-value-benchmark-ce7f5fdfdb89f126", "source_name": "www.marketscreener.com", "published_at": "2026-06-28T15:10:18", "published_display": "28 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Eikon Therapeutics, Inc. \u2013 BOATS:EIKN", "summary": "The article discusses the Enterprise Value to EBIT forward metric for Eikon Therapeutics, Inc. (EIKN). It provides a brief overview of the company's financial data as listed on TradingView, indicating that the market is currently closed with no trades. The content primarily focus", "url": "https://www.tradingview.com/symbols/BOATS-EIKN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T23:09:35", "published_display": "26 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Eikon Therapeutics, Inc. \u2013 NASDAQ:EIKN", "summary": "This article focuses on the \"Price to book forward\" metric for Eikon Therapeutics, Inc., traded on the Nasdaq Stock Market under the ticker EIKN. It appears to be an announcement or a data point provided by TradingView, indicating a specific financial ratio for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-EIKN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T23:09:35", "published_display": "26 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EIKN - Eikon Therapeutics Inc Short Interest", "summary": "This article provides comprehensive financial data for Eikon Therapeutics Inc. (EIKN), focusing on its short interest. It details key financial metrics, stock performance, insider and institutional ownership, analyst recommendations, and various valuation ratios. The data highlig", "url": "https://finviz.com/stock?t=EIKN&ta=1&p=d&ty=si", "source_name": "Finviz", "published_at": "2026-06-26T12:10:11", "published_display": "26 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics to Join the Russell 3000\u00ae Index", "summary": "Eikon Therapeutics, a late-stage clinical biopharmaceutical company, announced its inclusion in the broad-market Russell 3000\u00ae Index, effective after the US market closes on June 26, 2026. This addition highlights Eikon's progress as a publicly traded entity and its growing prese", "url": "https://www.globenewswire.com/news-release/2026/06/25/3317939/0/en/eikon-therapeutics-to-join-the-russell-3000-index.html", "source_name": "GlobeNewswire", "published_at": "2026-06-26T10:09:44", "published_display": "26 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Eikon Therapeutics, Inc. \u2013 NASDAQ:EIKN", "summary": "This article provides access to the enterprise value to EBITDA forward data for Eikon Therapeutics, Inc. (NASDAQ: EIKN) on TradingView. It appears to be a financial data page rather than a traditional article. The page is a directory for financial metrics and general company info", "url": "https://www.tradingview.com/symbols/NASDAQ-EIKN/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T10:09:18", "published_display": "26 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Eikon Therapeutics, Inc. \u2013 NASDAQ:EIKN", "summary": "This article provides the \"Price to sales forward\" value for Eikon Therapeutics, Inc. (NASDAQ: EIKN). It is a finance-related piece from TradingView, focusing on the company's financial metrics. The specific value for the forward price-to-sales ratio is presented as part of the c", "url": "https://www.tradingview.com/symbols/NASDAQ-EIKN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T03:41:18", "published_display": "26 Jun 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics, Inc. Actuals & Estimates (NASDAQ:EIKN)", "summary": "This article provides actuals and estimates for Eikon Therapeutics, Inc. (NASDAQ:EIKN), detailing its financial performance, stock price dynamics, and analyst forecasts. It covers the current stock price, historical highs and lows, market capitalization, volatility, and upcoming ", "url": "https://www.tradingview.com/symbols/NASDAQ-EIKN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T02:41:18", "published_display": "26 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Eikon Therapeutics, Inc. \u2013 BOATS:EIKN", "summary": "This article provides the \"Price to book forward\" financial metric for Eikon Therapeutics, Inc. (EIKN), listed on the Blue Ocean Alternative Trade System (BOATS). It presents the period, value, change, and percentage change. The content appears to be a snapshot from a financial d", "url": "https://www.tradingview.com/symbols/BOATS-EIKN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T00:41:18", "published_display": "26 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Eikon Therapeutics, Inc. \u2013 BOATS:EIKN", "summary": "This article provides financial information for Eikon Therapeutics, Inc. (EIKN) on the Blue Ocean Alternative Trade System (BOATS), specifically focusing on its forward price-to-earnings ratio. It indicates that the market is currently closed with no trades. The content is primar", "url": "https://www.tradingview.com/symbols/BOATS-EIKN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T23:09:18", "published_display": "25 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics to Join Russell 3000 Index After Annual Reconstitution", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/eikon-therapeutics-join-russell-3000-204829026.html", "source_name": "MT Newswires", "published_at": "2026-06-25T20:48:29+00:00", "published_display": "25 Jun 2026 20:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics to join Russell 3000 Index on Friday", "summary": "Eikon Therapeutics (NASDAQ:EIKN) will be added to the Russell 3000 Index after the U.S. market closes on Friday, following the annual reconstitution of Russell U.S. Indexes. The biopharmaceutical company is currently trading at $9.85 with a market capitalization of $521 million, ", "url": "https://www.investing.com/news/company-news/eikon-therapeutics-to-join-russell-3000-index-on-friday-93CH-4761442", "source_name": "Investing.com", "published_at": "2026-06-25T21:41:18", "published_display": "25 Jun 2026 21:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics to join Russell 3000 Index on Friday By Investing.com", "summary": "Eikon Therapeutics, Inc. (NASDAQ:EIKN) will be added to the Russell 3000 Index after the U.S. market closes on Friday, following the annual reconstitution of the Russell U.S. Indexes. The company currently trades at $9.85 with a market capitalization of $521 million, though share", "url": "https://ca.investing.com/news/stock-market-news/eikon-therapeutics-to-join-russell-3000-index-on-friday-93CH-4708308", "source_name": "Investing.com Canada", "published_at": "2026-06-25T20:25:47", "published_display": "25 Jun 2026 20:25", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Eikon Therapeutics, Inc. \u2013 NASDAQ:EIKN", "summary": "This article provides a financial snapshot of Eikon Therapeutics, Inc. (NASDAQ: EIKN), specifically focusing on its forward price-to-earnings ratio. It indicates that the market is currently closed for the stock, with no trades recorded. The content seems to be a financial data p", "url": "https://www.tradingview.com/symbols/NASDAQ-EIKN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T15:40:47", "published_display": "25 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EIKN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed forecast and price target for Eikon Therapeutics, Inc. (EIKN) stock, including analyst ratings and future predictions. It covers current market performance, historical highs and lows, volatility, market capitalization, and upcoming earnings report", "url": "https://www.tradingview.com/symbols/NASDAQ-EIKN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-24T02:09:44", "published_display": "24 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics Ord Shs (EIKN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Eikon Therapeutics Ord Shs (EIKN), detailing analyst ratings, target prices, and EPS estimates. Six analysts currently rate EIKN as a \"Buy\" with a target price suggesting a significant upside. The report also includes past EPS perfor", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eikn/earnings", "source_name": "TradingKey", "published_at": "2026-06-22T00:10:20", "published_display": "22 Jun 2026 00:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Stock: Buy TLR Combinatory Potential Only After Lock-Up Expiry (NASDAQ:EIKN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOOUxWelR4WFpBSHQ0SHFaNzBKRnZmazZ0Y09OV3N1MTVtUUJ0TmItTXdfYVJTZFpmRTlOT0xmMk12NjVKRW1yY3RLTkdkVHhhNTRRY0dzdDhDSFdDZnhtX3k3M0J3U2hGZEw1MzhLQVBuSVdEdEw3dk9YRnQxQjB2NXJKUTdfT0s5RFZLaDctRjV0Y2Y5QzR1Y2NlVHZ0Z1JmYTRuVm1xdk1MaEJ2b3hNTEVKbktmdw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cooper Companies Stock: Is COO Underperforming the Healthcare Sector?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPWkdoUDRJdkh3QndoZ3J2OHBvOEJlMUFEYjc1X3pLZGFXUlJ6eS1iNXhpYzNyd1NSZGxPOUdDM0xnZW9RcS1kdWNwR0xydVFVcEFGVmhfWWF5SFhYTmR5dXM0cTRIUENtbTc5bUpuNTNZQ0h0QWhMbnZDdGpfYjRWM2c3SWlCOHVJYTVoaUdDYnk2cTRKWWZTZHFvXzZDMTFmOGRUUUhyX3J6RUE?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics: Initiating Coverage With A Cautious Buy Rating (NASDAQ:EIKN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxObEdfNFZETEVGU3ZoQWVtd2haczVMb2ZodUlSeHBVcEpLcmJ1NW9nN3FZRk1KRGlUc0dRcF9tSGUwT2E3ZjgyRDdCdTN3aHlfaXpJVklVZkhYWHpjTm82MHJGWHJoSG5FWFdyWExxamRnYmFwRjlqYy01MzcybGlmMUstUmk5WjRZV0U3SUtvSXF3bHM1eTBzYjd0Q3RFanlPQjByaHdYajk2QQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics Appoints Ma. Fatima Francisco to Board", "summary": "Eikon Therapeutics, Inc. has appointed Ma. Fatima D. Francisco as a Class I director to its board, effective June 15, 2026. She will serve on the Compensation Committee and receive an annual cash retainer of $50,000, along with an option to purchase 85,937 shares. This appointmen", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2431328/eikon-therapeutics-appoints-ma-fatima-francisco-to-board/", "source_name": "The Globe and Mail", "published_at": "2026-06-12T03:10:30", "published_display": "12 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Former P&G business leader joins drug developer Eikon\u2019s board", "summary": "Eikon Therapeutics (Nasdaq: EIKN) has appointed Ma. Fatima D. Francisco, a former CEO at Procter & Gamble, as an independent director to its Board, effective June 15, 2026. She will also join the Board\u2019s Compensation Committee. Francisco brings over 35 years of leadership experie", "url": "https://www.stocktitan.net/news/EIKN/eikon-therapeutics-announces-the-appointment-of-ma-fatima-d-8v8p4pynn1cd.html", "source_name": "Stock Titan", "published_at": "2026-06-11T08:12:47", "published_display": "11 Jun 2026 08:12", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New director and stock option grant at Eikon Therapeutics (NASDAQ: EIKN)", "summary": "Eikon Therapeutics (NASDAQ: EIKN) has appointed Ma. Fatima D. Francisco to its Board of Directors as a Class I director, effective June 15, 2026. She will serve until the company's 2027 annual stockholder meeting and will join the Board's Compensation Committee. Ms. Francisco wil", "url": "https://www.stocktitan.net/sec-filings/EIKN/8-k-eikon-therapeutics-inc-reports-material-event-30cfff571ea9.html", "source_name": "Stock Titan", "published_at": "2026-06-11T03:10:30", "published_display": "11 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eikon-therapeutics-announces-appointment-ma-120000780.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T12:00:00+00:00", "published_display": "08 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Overweight on Eikon stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPck1INFR2M2xaVEhfMUsxRFotM0NuT2p3TXZ4QVB1VlkxX2pKalhkLTZJYzE0RjhtR2VtUUJmYWZjUzktTVV4YjlNOHpNQzl6Wi01N09KZUFSOF9xTlRteGFUb29WQ21YSGk4RkdXajFtV1l1aGp6cS1vSjBvT0lxVXhDcmpQRi03cWlNYlFFRjllUmgxU2tySWJwanlMTGkxMUJxMmR5Y0NkVHNtWUctbk1mNEM?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eikon-therapeutics-presents-data-clinical-183000633.html", "source_name": "GlobeNewswire", "published_at": "2026-05-30T18:30:00+00:00", "published_display": "30 May 2026 18:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eikon-therapeutics-announces-availability-six-210500443.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T21:05:00+00:00", "published_display": "21 May 2026 21:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$EIKN stock is down 10% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOY1NBNEVzQmZheWt2TnJqbGVPaXByOEZxWk1SWnRWVWZSX3NINUhPb2hGNlFjWUNybkhUTGhpRDd2QTQxT0hWOTRCbURrMnNxT1hDMGhWVlFjaWw1bWZGNFpZenJKZGp0RmctSmdKVWJPcnhpQ3JFdFF1UHVMSDFLZWJUVnNDN1c5UkoweHJ5QkRTalFPQ2NZNUxRbFVnLTBaOUZR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Cuts Price Target on Eikon Therapeutics to $5 From $7, Keeps Underperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-cuts-price-target-eikon-121145064.html", "source_name": "MT Newswires", "published_at": "2026-05-12T12:11:45+00:00", "published_display": "12 May 2026 12:11", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eikon-therapeutics-reports-first-quarter-200100054.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T20:01:00+00:00", "published_display": "11 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After a $381M IPO, Eikon fully enrolls a stage 4 lung cancer study", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNWE5sd2s5YkY4NmlRamZnbzk3aVZqRFBUNDV0ZEsxY09COE90eThxWXdRMVZpVl84ODR5TTFqa3QzYUdYWElXaVdpWEhISHdDRjVYSnlaNE9TbUhuQjhUOUI0blJ0RjJQYVhmVnE1YXVXTzVYYU8zTUJxOFhuVFNfUlRSZTE2eU1UV0l2Rk11dV81RE1rYjdPR0t2TFJhZDlyeFlieW9VQnhzSlhybFF4SWRjSG13cTBq?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eikon Therapeutics (EIKN) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE5IZUE4dzN1YXQ5MldXd19RTnRFa0Y4b2JmLS1NTDJVdl9FZnVZUjlaNURYS3haSkFjeEp1dkhxTWVzQmpBWUZHU3VzRmJaNFp6UGNoczlVckd0RUtOeUxfOUZPdlpXQQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-02-17T08:53:50+00:00", "published_display": "17 Feb 2026 08:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 73, "sentiment_summary": {"positive": 23, "negative": 3, "neutral": 47, "score": 57, "total": 73, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 26.5, "count": 45}, {"event": "earnings", "label": "Earnings", "weight": 9.15, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 3.65, "count": 6}, {"event": "guidance", "label": "Guidance", "weight": 2.0, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 23, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 9.77, "latest_week": "2026-07-17", "one_week_move": -7.7, "four_week_move": 1.7, "twelve_week_move": 1.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.0, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": -13.9, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 51.505, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-7.7% over one week, +1.7% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 12}, {"label": "Market source", "count": 9}, {"label": "www.marketscreener.com", "count": 5}, {"label": "GlobeNewswire", "count": 5}, {"label": "Stock Titan", "count": 4}, {"label": "Seeking Alpha", "count": 3}, {"label": "MarketBeat", "count": 2}, {"label": "MT Newswires", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 65}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 45}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 6}, {"label": "Guidance", "count": 3}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "65", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "8", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-7.7% over one week, +1.7% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Eikon Therapeutics: Behind The Rough Debut (NASDAQ:EIKN)"}], "updated_at": "2026-07-23T07:08:22.716622+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}